Health Care Innovation
California
A Single-Payer Healthcare System Would Have Made the Pandemic Worse
The intended-to-scare-readers headline said “California hospitals discuss rationing care as virus surges.” And it should frighten anyone who saw it. Though not necessarily for the reason the headline writer had in mind. The alarmist string of words topped a Dec. 21 Associated Press story, which warned that “overwhelmed hospitals” in ...
Kerry Jackson
January 4, 2021
Drug Pricing
NEW BRIEF: Tearing Down Drug ‘Rebate Walls’ Would Save Patients, Improve Health Care Outcomes
Tearing down drug “rebate walls” that increase patient costs and block access to cheaper and often more effective medications would increase competition, lower out-of-pocket costs, and improve health outcomes, finds a new brief released today by the Center for Medical Economics and Innovation at the nonpartisan Pacific Research Institute. Click ...
Wayne Winegarden
December 9, 2020
Commentary
For HHS post Biden taps ObamaCare’s lead defender – don’t expect him to be a moderate
President-elect Joe Biden announced Monday that he plans to nominate California Attorney General Xavier Becerra to be his Secretary of Health and Human Services. It’s a conventional, if unexpected, pick. The Washington rumor mill had New Mexico Governor Michelle Lujan Grisham and Rhode Island Governor Gina Raimondo as the front-runners to lead HHS until ...
Sally C. Pipes
December 8, 2020
Commentary
Trump wrongly attacks life-saving drug companies on coronavirus vaccines and more
President Trump announced Friday that he will proceed with his plans to peg the prices of certain drugs prescribed largely at doctors’ offices under Medicare Part B to the lower prices that other developed nations pay for those drugs. That may sound good at first glance, but in reality, the move will slow ...
Sally C. Pipes
November 23, 2020
Drug Importation
NEW BRIEF: Counterfeit Drugs Harm Patients, Economy, Innovation
A new brief released today by the Center for Medical Economics and Innovation at the nonpartisan Pacific Research Institute shows that counterfeit drugs put patients in harm’s way, hinder drug innovation, and lead to job losses. Proposals like drug importation or price controls, if implemented, would exacerbate the problem and ...
Pacific Research Institute
October 13, 2020
Commentary
Import German drug prices to the United States? Nein, danke
President Trump recently issued a blitz of executive orders in an attempt to fulfill his promise to reduce drug prices. One of those orders would put in place a “cure” far worse than the disease. The order in question establishes foreign reference pricing, whereby the federal government ties its reimbursement rates for ...
Sally C. Pipes
October 5, 2020
Drug Pricing
Wayne Winegarden Featured in Newsweek Drug Pricing Story
Title: Big Pharma Backs Joe Biden, But People Don’t Think He’ll Fix Drug Pricing By Darragh Roche Former Vice President Joe Biden is winning the race for donations from Big Pharma but experts and industry stakeholders doubt his plans will successfully lower drug prices or address underlying issues in the ...
Pacific Research Institute
September 29, 2020
Drug Pricing
NEW BRIEF: Mandating that Drug Rebates Benefit Consumers Will Help Patients with High Out-of-Pocket Drug Costs
A new brief released today by the Center for Medical Economics and Innovation at the Pacific Research Institute found that reforms mandating drug rebates benefit patients rather than payers would lower overall health care costs and help patients with expensive out-of-pocket drug costs. Click here to download the brief “Ironically, ...
Wayne Winegarden
September 29, 2020
Commentary
Price Controls Are Disastrous For Rents And Will Be For Drugs
President Trump and senior advisor Jared Kushner claim that the most favored nation executive order signed by the President over the weekend is necessary for drug pricing because “the U.S. shouldn’t pay more than other European countries for the same treatments.” This policy will make things worse, not better. If the president ...
Wayne Winegarden
September 15, 2020
Commentary
Trump’s Drug Pricing Order Is A Costly Mistake
On Sunday, September 13, President Trump signed a “most-favored-nation” executive order to reduce U.S. drug prices. It instructs federal officials to set pharmaceutical reimbursements under Medicare Parts B and D equal to the lowest prices paid in other developed countries, including Canada, the United Kingdom, and France. The high cost of medications is a ...
Sally C. Pipes
September 15, 2020
A Single-Payer Healthcare System Would Have Made the Pandemic Worse
The intended-to-scare-readers headline said “California hospitals discuss rationing care as virus surges.” And it should frighten anyone who saw it. Though not necessarily for the reason the headline writer had in mind. The alarmist string of words topped a Dec. 21 Associated Press story, which warned that “overwhelmed hospitals” in ...
NEW BRIEF: Tearing Down Drug ‘Rebate Walls’ Would Save Patients, Improve Health Care Outcomes
Tearing down drug “rebate walls” that increase patient costs and block access to cheaper and often more effective medications would increase competition, lower out-of-pocket costs, and improve health outcomes, finds a new brief released today by the Center for Medical Economics and Innovation at the nonpartisan Pacific Research Institute. Click ...
For HHS post Biden taps ObamaCare’s lead defender – don’t expect him to be a moderate
President-elect Joe Biden announced Monday that he plans to nominate California Attorney General Xavier Becerra to be his Secretary of Health and Human Services. It’s a conventional, if unexpected, pick. The Washington rumor mill had New Mexico Governor Michelle Lujan Grisham and Rhode Island Governor Gina Raimondo as the front-runners to lead HHS until ...
Trump wrongly attacks life-saving drug companies on coronavirus vaccines and more
President Trump announced Friday that he will proceed with his plans to peg the prices of certain drugs prescribed largely at doctors’ offices under Medicare Part B to the lower prices that other developed nations pay for those drugs. That may sound good at first glance, but in reality, the move will slow ...
NEW BRIEF: Counterfeit Drugs Harm Patients, Economy, Innovation
A new brief released today by the Center for Medical Economics and Innovation at the nonpartisan Pacific Research Institute shows that counterfeit drugs put patients in harm’s way, hinder drug innovation, and lead to job losses. Proposals like drug importation or price controls, if implemented, would exacerbate the problem and ...
Import German drug prices to the United States? Nein, danke
President Trump recently issued a blitz of executive orders in an attempt to fulfill his promise to reduce drug prices. One of those orders would put in place a “cure” far worse than the disease. The order in question establishes foreign reference pricing, whereby the federal government ties its reimbursement rates for ...
Wayne Winegarden Featured in Newsweek Drug Pricing Story
Title: Big Pharma Backs Joe Biden, But People Don’t Think He’ll Fix Drug Pricing By Darragh Roche Former Vice President Joe Biden is winning the race for donations from Big Pharma but experts and industry stakeholders doubt his plans will successfully lower drug prices or address underlying issues in the ...
NEW BRIEF: Mandating that Drug Rebates Benefit Consumers Will Help Patients with High Out-of-Pocket Drug Costs
A new brief released today by the Center for Medical Economics and Innovation at the Pacific Research Institute found that reforms mandating drug rebates benefit patients rather than payers would lower overall health care costs and help patients with expensive out-of-pocket drug costs. Click here to download the brief “Ironically, ...
Price Controls Are Disastrous For Rents And Will Be For Drugs
President Trump and senior advisor Jared Kushner claim that the most favored nation executive order signed by the President over the weekend is necessary for drug pricing because “the U.S. shouldn’t pay more than other European countries for the same treatments.” This policy will make things worse, not better. If the president ...
Trump’s Drug Pricing Order Is A Costly Mistake
On Sunday, September 13, President Trump signed a “most-favored-nation” executive order to reduce U.S. drug prices. It instructs federal officials to set pharmaceutical reimbursements under Medicare Parts B and D equal to the lowest prices paid in other developed countries, including Canada, the United Kingdom, and France. The high cost of medications is a ...